1. Genetics of Adrenal disease (Basic)

1. Lessons from Nature – P450 oxidoreductase deficiency and androgen synthesis
Wiebke Arlt (UK)

2. Genetics of Primary Pigmented Nodular Adrenocortical Disease
Constantine Stratakis (USA)

3. New developments in ACTH insensitivity
Adrian Clark (UK)

2. Adrenocortical development (Basic)

1. Transcriptional regulation of adrenal stem cell development
Gary Hammer (USA)

2. An adrenocortical enhancer regulates developmental expression of steroidogenic factor 1
Ken Morohashi (JP)

3. Zebrafish models of adrenal development
Bon-chu Chung (TW)

3. Adrenal Cancer (Translational)

1. Adrenocortical cancer in children: the Brazilian experience
Romalu Sandrini (BR)

2. The medical management of adrenocortical cancer
Massimo Terzolo (IT)

3. Diagnosis and management of malignant pheochromocytoma
Karel Pacek (USA)

4. Primary aldosteronism (Clinical)

1. The diagnosis of primary hyperaldosteronism
Richard Auchus (USA)

2. Medical versus surgical treatment of primary hyperaldosteronism

3. Non-tumorous hyperaldosteronism: a digenic phenomenon?
John Connell (UK)

5. Cushing's Syndrome (Clinical)

1. The molecular basis of corticotroph development and disease
Thierry Brue (FR)

2. Diagnosis of Cushing’ Syndrome
John Newell Price (UK)

3. Nelson’s Syndrome
Guillaume Assié (FR)

6. Phaeochromocytoma (Clinical)

1. Genetics of phaeocromocytoma in Chinese patients
Zhengpei Zeng (CN)

2. What is the optimal roadmap to the diagnosis of phaeochromocytoma?
Jacques Lenders (NL)

3. Perioperative management of phaeochromocytoma
Hartmut Neumann (DE)

1. Endocrinology and paracrinology of bone: who is in charge? (Basic)

1. Immune cell products in regulation of osteoclast biology: formation and action
Robert Pacifici (USA)

2. Paracrinology in bone: PTH, PTHrP and vitamin D relationships
D Goltzman (Ca)

3. Are hormone receptors involved in mechanical stimulation of bone?
Lance Lanyon (UK)

2. FGF23 and klotho in mineral metabolism and aging (Basic)

1. Control of FGF23 action by klotho: implications for phosphate metabolism
Seiji Fukumoto (JP)

2. Klotho regulation of calcium transport
Y. Nabeshima (JP)

3. FGF23, klotho, vitamin D and ageing
Beate Lanske (USA)

3. Bone resorption control and new therapeutic strategies (Translational)

1. Regulation of RANK ligand production and its signalling in osteoclast formation
Noboyuki Udagawa (JP)

2. Anti-RANKL treatment in osteoporosis and skeletal complications of cancer
Lorenz Hofbauer (DE)

3. Combining anti-resorptive with anabolic treatments for osteoporosis.
Robert Neer (USA)

4. Building bones: current and coming anabolic agents (translational)

1. How PTH builds bone
G. Krishnan (USA)

2. Discovery and biology of the SOST gene
Wim Van Hul (BE)

3. Anti-sclerostin as an anabolic therapy for bone
Xiaodong Li (USA)

5. Populations genetics in the evaluation of osteoporosis diagnosis and treatment (Clinical)

1. Genome-wide association scans in osteoporosis
Tim Spector (UK)

2. Genetics of fractures in males and females
Andre Uitterlinden (NL)

3. Has genetics allowed us to identify target groups for treatment?
John Eisman (AU)

6. Therapies for osteoporosis (Clinical)

1. Absolute fracture risk and changing burden of disease internationally.
Cyrus Cooper (UK)

2. What can be achieved with anti-resorptive drugs?
Peter Ebeling (AU)

3. Treatment – why, whom, when, what drug, and for how long?
Michael McClung (USA)

7. Hyperparathyroidism (Clinical)

1. Hyperparathyroidism and multiple endocrine neoplasia type 1 (MEN1)
Stephen Marx (USA)

2. Medical management of primary hyperparathyroidism – patient selection and efficacy
John Bilezikian (USA)

3. Conservative management of primary hyperparathyroidism
J Bollerslev (NO)

1. Life and Death of the Beta-cell (Basic)

1. Regulation of cell cycle and control of beta-cell mass.
Ernesto Bernal-Mizrachi (USA)

2. Role of NF-kB in beta-cell death in models of Type I Diabetes Mellitus
Danielle Melloul (IL)

3. Animal models of beta-cell regeneration
Pedro Herrera (SW)

2. Mitochondria and Diabetes (Basic)

1. Mitochondrial contribution to type 2 diabetes: Pathogenesis involves dysfunction of beta cells and adipose tissue
L. Peltonen (HL)

2. UCP2 as a therapeutic target for the treatment of diabetes
Chen-Yu Zhang (CN)

3. The role of mTOR in the beta-cell adaptation to hyperglycemia and oxidative stress in Type 2 diabetes
Gil Leibowitz (IL)

3. Endoplasmic reticulum Stress signalling in Diabetes and Obesity

1. Overview - endoplasmic reticulum stress signalling
David Ron (USA)

2. PNAS on proinsulin folding, misfolding and proteotoxicity
P. Arvan (USA)

3. Endoplasma reticulum stress, beta-cell function and apoptosis -
Decio Eizirik (BE)

4. Visceral obesity and co-morbidity (Translational)

1. New insights into NAFLD pahophysiology
Hannele Yki-Jarvinen (FI)

2. Protective roles of adiponectin in obesity-related fatty liver diseases
Yu Wang (HK)

3. Protective molecular and endocrine mechanisms after caloric restriction
Eric Ravussin (USA)

5. What works for diabetes and obesity prevention in a public health setting (Translational)

1. Policy and National Strategy
Philip James (UK)

2. Role of the Food Industry in the Prevention of Obesity
Derek Yach (USA)

3. Lifestlye intervention to reduce diabetes and beyond- the Chinese experience
GW Li (CN)

6. Cutting edge therapies for diabetes (Translational)

1. New forms of insulin delivery
Tadej Battelino (SI)

2. Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
Júlio Voltarelli (BR)

3. Transplantation Treatments for Type 1 Diabetes Mellitus
David Harlan (USA)

7. Type 2 Diabetes: a gut hormones' war (Translational)

1. Incretins: an alpha and beta cell fight
Dan Drucker (CA)

2. Incretin-based therapy: fighting obesity & defeating type 2 Diabetes Mellitus
Filip Knop (DK)

3. Incretins: beyond the glucose arena
Michael Nauck (DE)

8. New Modalities for the Treatment Obesity and Diabetes (Clinical)

1. Endocannabinoids and the Control of Energy Balance
Uberto Pagotto (IT)

2. Gastrointestinal operations that eliminate diabetes: Mechanisms and prospects
David E. Cummings (USA)

3. Drug therapy in obesity and diabetes: reconciliating the new and the old

9. Pediatric Type 2 diabetes mellitus - an emerging epidemic (Clinical)

1. Childhood obesity: contribution of maternal factors
Ranjan Yajnik (IN)

2. Pathogenesis of Type 2 Diabetes Mellitus in Youth: An Evolving Chameleon
Sylivia Arslanian (USA)

3. Obesity and Metabolic Syndrome in adolescents - therapeutic options
Martin Wabitsch (DE)

10. Inpatient management of the diabetic patient (Clinical)

1. Glycemic control in the intensive care unit: Are we making a difference?
Greet Van den Berghe (BE)

2. Management of Inpatient Hyperglycemia: Facts or Fiction
Guillermo Umpierrez (USA)

11. Diabetes -- Major outcome studies (Clinical)

1. What have we learned from recent clinical trials?
Steve Kahn (USA)

2. Critical re-evaluation of therapy guidelines

3. Critical re-evaluation of therapy guidelines

1. New Frontiers in Activin and Inhibin Function (Basic)

1. Activin regulation of gonadotropin synthesis
Daniel J. Bernard

2. Regulation of adipocyte activin during weight loss
Lena MS Carlsson (SE)

3. Regulation of Inhibin Subunit Gene Expression
Kelly Mayo (USA)

2. New aspects in sex differentiation (Basic)

1. Signalling at the Crossroads of Development
Blanche Capel (USA)

2. New genes and mechanisms for sex development
Tsutoma Ogata (JP)

3. Retinoid signalling and gonadal sex differentiation
Peter Koopman (AU)

Nov. 10
(1 - 2:30pm)

3. Anti-Mullerian Hormone (AMH): an expanding tool in Reproductive Endocrinology and Oncology (Translational)

1. AMH in disorders of gonadal function in infancy and childhood
Rodolfo Rey (AR)

2. Ovarian AMH production: Implications for the diagnosis of ovarian reserve
Axel Themmen (NL)

3. MIS as a therapeutic agent
David MacLaughlin (USA)

4. Epigentic control of Reproduction (Translational)

1. piRNAs in Mouse

2. Epigenetic Decision in Mammalian Germ cells Spermatogenesis
Deborah Bourc'his (FR)

3. Mismatch Repaire in meiosis
Paula Cohen (USA)

5. Metabolic dysfunction and long-term health risks in PCOS (Clinical)

1. Obesity and Lifestyle Management in PCOS
Kathy Hoeger (USA)

2. Nutrition, insulin resistance and PCOS
Lisa Moran (AU)

3. Metabolic syndrome and PCOS
John Nestler (USA)

6. Menopause and HRT (Clinical)

1. Menopausal transition
John F. Randolph (USA)

2. Phytoestrogens and cardiovascular disease in the menopause
Helena Teede (AU)

3. Phytoestrogens and climacteric complaints, the bone and the cardiovascular system
Wolfgang Wuttke (DE)

7. New Aspects in Testosterone and Men (Clinical)

1. Testosterone and the heart
Kevin Channer (UK)

2. Large Scale Clinical Trial of Hormonal Male Contraception in China Using Testosterone Undecanoate in Tea Seed Oil
Yi-Qun Gu (CN)

3. Male hormonal contraceptive strategies: insights into the endocrine requirements of spermatogenesis
Rob McLachlan (AU)

1. Novel biomarkers in pituitary tumorigenesis (Basic)

1. GDNF/Ret as a survival signal in pituitary
Clara V. Alvarez (SP)

2. Identifying new targets for pituitary tumor treatment
Marily Theodoropoulou (DE)

3. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity
Alfredo Fusco (IT)

2. Pituitary development (Basic)

1. Early pituitary development: news from the sonic hedgehog cascade
Roland Pfaeffle (DE)

2. Regulators of pituitary development revealed using genetically engineered mice
Sally Camper (USA)

3. New genes involved in pituitary cell regulation
Eduardo Arzt (AR)

Nov. 10
(9:30 - 11am)

3. Understanding hypopituitarism (Translational)

1. Animal models of adult-onset GH-deficiency
Rhonda D. Kineman (USA)

2. Hypopituitarism after brain damage: Clinical relevance and practice guidelines

3. New concepts in hormone replacement therapy
Georg Brabant (UK)

4. Regulation of hypothalamic-pituitary crosstalk (Translational)

1. Alterations in metabolism induced by sleep loss
Karine Spiegel (FR)

2. Novel approaches in the treatment of hypothalamic obesity
Robert Lustig (USA)

3. Adipokines as hypophysiotropic factors
M. M. Malagón (SP)

5. GH in adults (Clinical)

1. GH deficiency in adults
Jens S. Christiansen (DK)

2. New views of Quality-of-Life Testing in GH deficiency
Susan Webb (SP)

3. GH treatment for the frail elderly
Andrew R. Hoffman (US)

6. Pituitary hyperfunction (Clinical)

1. Clinical potential of AVP receptor antagonists
Joseph G. Verbalis (USA)